Skip to main content

Table 3. Sensitivity analysis by leave-one-out method

From: Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials

Study excluded

Malignancy

NMSC

Malignancy excluding NMSC

SAE

Death

Burmester [18]

1.42 (0.59, 3.41)

1.44 (0.36, 5.76)

1.12 (0.40, 3.13)

1.12 (0.87, 1.45)

2.03 (0.73, 5.64)

Fleischman [19]

1.97 (0.75, 5.16)

2.01 (0.43, 9.35)

1.53 (0.48, 4.83)

1.14 (0.87, 1.49)

1.70 (0.61, 4.77)

Fleischman [20]

1.24 (0.50, 3.12)

1.18 (0.25, 5.47)

0.99 (0.33, 2.91)

1.21 (0.92, 1.59)

1.76 (0.63, 4.92)

Genovese [21]

1.41 (0.56, 3.53)

1.44 (0.36, 5.76)

1.09 (0.37, 3.21)

1.16 (0.91, 1.49)

1.99 (0.75, 5.27)

Van der Heijde [25]

1.64 (0.65, 4.14)

1.75 (0.36, 8.61)

1.20 (0.40, 3.61)

1.13 (0.88, 1.46)

1.95 (0.64, 5.89)

Kivitz [22]

1.42 (0.59, 3.41)

1.44 (0.36, 5.76)

1.12 (0.40, 3.13)

1.16 (0.90, 1.48)

1.99 (0.75, 5.27)

Kremer [23]

1.43 (0.57, 3.58)

1.49 (0.32, 6.99)

1.12 (0.40, 3.13)

1.16 (0.90, 1.48)

1.99 (0.75, 5.27)

Li [24]

1.42 (0.59, 3.41)

1.44 (0.36, 5.76)

1.12 (0.40, 3.13)

1.15 (0.90, 1.48)

2.37 (0.85, 6.59)

Takeuchi [26]

1.22 (0.48, 3.09)

Not estimated

Not estimated

1.19 (0.93, 1.54)

1.99 (0.75, 5.27)

Tanaka [27]

1.42 (0.59, 3.41)

1.44 (0.36, 5.76)

1.12 (0.40, 3.13)

1.15 (0.90, 1.48)

1.99 (0.75, 5.27)

Taylor [28]

1.17 (0.41, 3.37)

1.02 (0.22, 4.73)

0.99 (0.28, 3.46)

1.12 (0.84, 1.48)

2.51 (0.85, 7.37)

Vollenhoven [29]

1.37 (0.54, 3.43)

1.44 (0.36, 5.76)

1.03 (0.35, 3.08)

1.16 (0.90, 1.50)

1.82 (0.65, 5.05)

Westhovens [30]

1.42 (0.59, 3.41)

1.44 (0.36, 5.76)

1.12 (0.40, 3.13)

1.10 (0.86, 1.42)

1.95 (0.70, 5.43)

  1. NMSC non melanomatous skin cancer, SAE serious adverse events